Targeted agents for HER2-positive breast cancer: Optimal use in older patients Journal Article

   


Authors: Singh, J. C.; Lichtman, S. M.
Article Title: Targeted agents for HER2-positive breast cancer: Optimal use in older patients
Abstract: The HER2 gene is overexpressed in 15–20 % of all breast cancers. With the advent of HER2-directed therapies, HER2 overexpression is no longer considered an adverse prognostic factor. Despite significant improvements in clinical outcomes with the use of trastuzumab [herceptin (H)], women aged >65 years remain under-represented in most clinical trials. Cardiac safety in the elderly woman is a major concern because of pre-existing comorbidities. However, many studies suggest that elderly patients with HER2-positive disease derive the same benefit from trastuzumab as do their younger counterparts in both adjuvant and metastatic settings. Data are limited guiding safety and efficacy of other HER2 inhibitors such as pertuzumab and trastuzumab emtansine in elderly patients; however, in general, these drugs have a favorable toxicity profile. © 2015, Springer International Publishing Switzerland.
Keywords: treatment outcome; aged; fatigue; doxorubicin; fluorouracil; diarrhea; drug efficacy; drug safety; capecitabine; paclitaxel; multiple cycle treatment; breast cancer; vomiting; epidermal growth factor receptor 2; cyclophosphamide; docetaxel; exemestane; asthenia; cardiotoxicity; comorbidity; epirubicin; trastuzumab; navelbine; anthracycline; breast metastasis; elderly care; everolimus; lapatinib; pertuzumab; dysgeusia; phosphatidylinositol 3 kinase inhibitor; clinical trial (topic); molecularly targeted therapy; decreased appetite; trastuzumab emtansine; human; priority journal; article; heart muscle injury
Journal Title: Drugs & Aging
Volume: 32
Issue: 12
ISSN: 1170-229X
Publisher: Adis International Ltd  
Date Published: 2015-12-01
Start Page: 975
End Page: 982
Language: English
DOI: 10.1007/s40266-015-0326-1
PROVIDER: scopus
PUBMED: 26645293
PMCID: PMC4991772
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84949554585&partnerID=40&md5=dd0e47f0e7f3624257130b1fa2fd8116
Notes: Article -- Export Date: 7 January 2016 -- 975 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Stuart Lichtman
    228 Lichtman
  2. Jasmeet Chadha Singh
    23 Singh
Related MSK Work